Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Arrows
Introducing Scrip 100 2018: analyzing the biopharma sector • Source: Shutterstock

The Scrip 100 examines the financial performance of all companies that sell more than $1m worth of prescription drugs or spend more than $1m on drug-related R&D. Confusingly, the universe of companies we looked at for FY 2016 is more Scrip 1000 than Scrip 100: it encompasses 659 companies (from over 750 researched), mammoths to minnows, generics to gene therapy, from Slough to Summit, AB Science to Zynerba Pharmaceuticals, from Seoul to Rockville.

To make things simpler, this introduction focuses on the one hundred companies that make the most revenue from selling prescription...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.